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Available online 7 November 2013The incretin hormone glucagon-like peptide-1 (GLP-1) (7-36)-based therapeutic strategies have been shown to
have cardioprotective properties in animal models of ischemia and infarction due to promotion of myocardial
glucose uptake and suppression of cardiac cell apoptosis. However, in patient with myocardial infarct, GLP-1 an-
alogues' capacity to effectively protect the heart from dysfunction caused by supply ischemia during percutane-
ous coronary intervention is still limited. We herein review routine use of a GLP-1 receptor agonist, exenatide in
patients with ST-segment elevation myocardial infarction at the time of primary percutaneous coronary inter-
vention, highlightmultiple pleotrophic effects and point out several important clinical issues that require consid-
eration and exploration.
© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.1. Introduction
Cardiac cell apoptosis activation determines the ﬁnal myocardial
infarction (MI) size, subsequent mortality and post-MI remodeling
during myocardial infarction [1]. Over the past decade, glucose–insulin–
potassium infusion has been postulated to possess antiapoptosis-related
cytoprotective potential and has been investigated in several clinical
trials for cardioprotection in patients with ST-segment elevationmyocar-
dial infarction (STEMI).2 However,most studies showedminor or no ben-
eﬁcial cardiac effects [2,3]. Clinical and experimental research has focused
on glucagon-like peptide-1 (GLP-1) as a potential agent to protect MI pa-
tients and animals from cardiac damage. GLP-1 [(7-36) amide], an
incretin hormone, is secreted mainly by the intestinal L cells in response
to meals [4]. GLP-1 has been shown to facilitate insulin release and miti-
gates the risks of hypoglycemia [4]. However, it was reported that after
secretion, GLP-1 is targeted rapidly by serine protease dipeptidyl
dipeptidase-4 for degradation to GLP-1 (9-36), a weak antagonist
of GLP-1R without incretin activity [1,5]. Thus, therapeutic strategies
have been developed that are designed to increase the presence of
GLP-1 (7-36) in blood, either by inhibiting DPP-4 activity or by using, Nagoya University Graduate
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management of patients with diabetes mellitus [1].
Accumulating evidence shows that GLP-1 has multiple pleotrophic
effects, those beyond lowering glucose alone by stimulating insulin
[6–8]. These additional beneﬁts of GLP-1 and GLP-1 receptor agonists
(i.e., antiapoptosis [3], nitric oxide-dependent endothelial function
improvement [9], atrial natriuretic peptide-dependent blood pressure
reduction [10], anti-inﬂammation [1,11], and antioxidative stress [12])
have most likely been partially responsible for the cardiovascular
beneﬁcial effects of this class of agents (Fig. 1).
In the current issue of Arteriosclerosis, Thrombosis, and Vascular
Biology, Woo and co-workers explore the possibility of an exenatide-
mediated protective effect on ischemia-reperfusion injury-induced
myocardial damage, bymonitoring the changes in serumMI-related en-
zymes including creatine kinase-MB and troponin I in STEMI patients
undergoing primary percutaneous coronary intervention (PCI) [13].
The observations show that exenatide treatment caused marked
reductions of the serum levels of both creatine kinase-MB and troponin
I. Cardiac magnetic resonance evaluation data showed that the infarct
size and the absolute mass of the infarct area were markedly decreased
in the exenatide group at the 1-month follow-up, which is consistent
with the study's hypothesis. These impressive ﬁndings conﬁrm
that agonist-mediated GLP-1 receptor activation can have powerful
cytoprotective effects in patients with STEMI undergoing PCI.
Another possiblemechanism bywhich GLP-1 receptor agonistmod-
ulates inﬂammatory responses was also investigated byWoo et al. [13].
Serum high-sensitivity C-reactive protein (hs-CRP) as a biomarker has
been often targeted in studies of inﬂammatory diseases such as
atherosclerosis-based coronary artery disease [14,15]. In the study by-SA license.
Fig. 1. The cardiovascular protective actions mediated by glucagon-like peptide-1 GLP and GLP-1 receptor agonists in atherosclerosis-based cardiovascular disease. NO, nitric oxide; ANP,
atrial natriuretic peptide.
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increased levels of serumhs-CRP. At the 1-month follow-up, the authors
observed that the baseline-adjusted levels of hs-CRP were decreased in
the exenatide-treated patients. To investigate the ability of exenatide to
reduce hs-CRP levels, the reduction rate of hs-CRP b3.0 mg/L was eval-
uated. Interestingly, Woo et al. observed that the reduction of hs-CRP
b3.0 mg/L was associated with exenatide treatment. This notion was
further supported by the results of amultivariate analysis adjusting con-
comitant medications; that is, that there is a close relationship between
adjunctive exenatide therapy and the reduction of hs-CRP levels (haz-
ard ratio, 2.55 [95% conﬁdential interval, 1.29–4.07]; P b 0.05). Recent
data fromour group and other researchers have demonstrated that aug-
menting GLP-1 activity exhibits cardiovasculoprotective actions
through the reduction of macrophage activation or/and inﬂammatory
cytokine production in several animal models [11,12,16]. Thus, to the
best of our knowledge, the present study is the ﬁrst to show that the
pharmacological activation of GLP-1 receptor (GLP-1R) may confer
cardioprotection via anti-inﬂammation against cardiac injury.
Next,Woo and colleagues examined the efﬁcacy of exenatide on car-
diac dysfunction at a 6-month follow-up [13]. Serial routine echocardi-
ography examinations demonstrated that the exenatide therapy had
beneﬁcial effects on decreased left ventricular ejection fraction and in-
creased E/E′ ratio. Speckle tracking echocardiography study also con-
ﬁrmed that the exenatide group showed a signiﬁcantly lower global
longitudinal rate, global longitudinal rate ratios, and global circumferen-
tial strain compared to the control subjects. Thus, GLP-1R activation
appears to improve cardiac systolic and diastolic dysfunction. It should
be noted that at the early time point of the 3-day follow-up, with the
exception of the global longitudinal rate and its ratio, exenatide showed
no effects on other cardiac functional parameters, suggesting that the
acute cardiac beneﬁcial effects of exenatide are inadequate.
Finally,Woo et al have challenged the hypothesis regarding the pos-
sibility of the inﬂuence of diabetes mellitus or culprit artery difference
on exenatide-mediated beneﬁcial effects [13]. The data from a sub-
analysis showed that salient cardioprotective effects were observed in
patients with diabetes and anterior MI, although these are small num-
bers of patients. Non-diabetic patients with STEMI have been enrolled
in clinical trials [6–8,17] that evaluated the cardioprotective effect of
exenatide. Only a small number of studies have examined the effectsof diabetes mellitus and culprit coronary artery difference on drug-
mediated cardioprotection in STEMI patients undergoing PCI [17].
Further clinical and basic research is needed to investigate this issue.
On the other hand, Woo et al. also evaluated the safety and tolerabil-
ity of exenatide treatment [13]. During the study period, no patients had
to stop using exenatide due to non-target effects. No patients exhibited
chest pain aggravation or vascular, renal or respiratory failure, but
there were signiﬁcant differences in blood pressure at 48 h after ran-
domization. Consistent with previous reports [18], gastrointestinal
symptoms (particularly nausea and vomiting) were more frequent in
the exenatide group compared to the corresponding control group. The
sensation of nausea that accompanies exenatide use might be due to
slowed gastric emptying, appetite suppression, and/or stimulation of
neural GLP-1 receptors, although no direct evidence of thesewas obtain-
ed. During exenatide therapy, careful attention is needed to avoid severe
hypoglycemia in patients taking the drugs that inﬂuence the blood sugar
(such as sulfonylurea and/or insulin).
The key ﬁndings from the study byWoo et al. [13]. are: (i) adjunctive
exenatide therapy with PCI alleviates reperfusion-induced cardiac inju-
ry and improves cardiac systolic and diastolic dysfunction in patients
with STEMI, (ii) patients with diabetes and anterior as culprit artery
showed salient cardioprotective effects, although a small number of
patients were included in the analysis.
Important limitations of the present study include the small sample
size, which to some extentmay account for the relatively large variation
in the evaluation of targeted andnon-targeted side effects. Other several
important clinical issues that require consideration and exploration
include: (i) whether baseline GLP-1 levels, traditional vascular disease
risk factors (age, gender, smoking, hypertension, diabetes, etc.),
confounding factors, genetic factors, pharmacological treatments
or existing heart disease affect exenatide-mediated cardiovascular
beneﬁts; (ii)whether the time, thedose, and the route of administration
enhance or mitigate exenatide's effects.
A few clinical and experimental studies reported that recombinant
GLP-1 or GLP-1R agonists exhibit insufﬁcient beneﬁts or are harmful to
cardiac injuries. In 2004, Nikolaidis et al. pointed out that the difference
in cardiac dysfunction improvement between their own study [17] and
the previous Dutch GIK study [2] was due to the timing of the recombi-
nant GLP-1 administration (after successful PCI vs. before reperfusion in
3X.W. Cheng et al. / IJC Metabolic & Endocrine 1 (2013) 1–3the GIK study), the proportion of diabetes (higher than in the GIK study),
and left ventricular function (better than in the GIK study). In addition,
the GLP-1R agonist dosage that has been reported is a mismatch. There
are also no useful standards regarding how long, how much, and which
routes are optimal for these drugs as treatment for patients withmyocar-
dial infarction undergoing PCI. A larger-scale clinical cohort study would
be useful to address some of these issues. On the other hand, the recent
literature highlights personalized medicine. As has been done with anti-
platelet clopidogrel, genetic and molecular approaches must be applied
to identify GLP-1R agonist responders or low- and non-responders in
order to guide their cardiovascular disease treatment.
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